Southeast Asia Olmesartan Market was valued at US$ 335.2 million in 2023 and is projected to surpass a valuation of US$ 518.8 million by 2032 at a CAGR of 4.3% during the forecast period 2024–2032. A ...
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback